LC3-dependent intercellular transfer of phosphorylated STAT1/2 elicits CXCL9+ macrophages and enhances radiation-induced antitumor immunity
Open Access
- 9 October 2025
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (23)
Abstract
The efficacy of anticancer treatments, including radiotherapy, depends on the activation of type I IFN signaling. However, its regulatory networks and mechanisms remain to be elucidated. Here, we report that tumor cell–intrinsic type I IFN signaling can be transferred to macrophages via secretory autophagy, inducing CXCL9 hi macrophages and enhancing CD8 + T cell–mediated antitumor immunity. Mechanistically, K63-linked ubiquitination at the K167 site of phosphorylated STAT2 (p-STAT2) facilitates its binding to LC3B, promoting the loading of p-STAT1 and p-STAT2 into extracellular vesicles and intercellular transference from tumor cells to macrophages, which, however, is suppressed by USP5-mediated STAT2 deubiquitination. Genetic depletion or pharmacological inhibition of USP5 promotes autophagy-dependent unconventional protein secretion of p-STAT1 and p-STAT2, leading to the induction of CXCL9 + macrophages. This process promotes the expression of T cell chemokines and upregulates the antigen presentation machinery, thereby enhancing radiation-induced CD8 + T cell antitumor immunity and radiotherapy efficacy. Our findings reveal a critical role of USP5 in type I IFN–induced antitumor immunity, providing potential targets for improving the efficacy of radiotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82403970,82172806)
- China Postdoctoral Science Foundation (2023TQ0389,GZB20230895)
- Young Talents Program of Sun Yat-sen University Cancer Center (YTP-SYSUCC-0010)
- Sun Yat-sen University Cancer Center (CIRP-SYSUCC-0005)
This publication has 58 references indexed in Scilit:
- Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppressionDevelopmental Cell, 2024
- Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialThe Lancet, 2024
- Tumor macrophage functional heterogeneity can inform the development of novel cancer therapiesTrends in Immunology, 2023
- FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2Journal of Hepatology, 2023
- Association of Intratumoral Microbiota With Prognosis in Patients With Nasopharyngeal Carcinoma From 2 Hospitals in ChinaJAMA Oncology, 2022
- The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaCancer Communications, 2021
- Nasopharyngeal carcinomaThe Lancet, 2019
- Secretory autophagyCurrent Opinion in Cell Biology, 2015
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic TumorsImmunity, 2014
- Macrophage Activation and Polarization: Nomenclature and Experimental GuidelinesImmunity, 2014